Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers

For the second time in a week, Zealand Pharma’s weight loss pipeline has delivered mixed results, this time in a Phase 2 trial for the Roche-partnered asset petrelintide.